Federal Register / Vol. 86, No. 140 / Monday, July 26, 2021 / Notices 40065 

such reports shall be in such form, with 

such content, as specified by the 

Secretary in future program instructions 

directed to all Recipients,’’ will be using 

the PRF Reporting Portal to submit 

information about their use of PRF 

payments. HRSA is currently operating 

under the Paperwork Reduction Act 

Public Health Emergency (PHE) waiver 

that was approved by the Office of the 

Assistant Secretary for Planning and 

Evaluation on January 14, 2021. In 

anticipation of the PHE waiver expiring, 

HRSA is undergoing the OMB clearance 

process as the data will be collected 

beyond the PHE. 

Need and Proposed Use of the 

Information: Recipients of a PRF 

payment agreed to a set of Terms and 

Conditions, which, among other 

requirements, mandate compliance with 

certain reporting requirements that will 

facilitate appropriate oversight of 

recipients’ use of funds. 

Information collected will allow for 

(1) assessing whether recipients have 

met statutory and programmatic 

requirements, (2) conducting audits, (3) 

gathering data required to report on 

findings with respect to the 

disbursements of PRF payments, and (4) 

program evaluation. HRSA staff will 

also use information collected to 

identify and report on trends in health 

care metrics and expenditures before 

and during the allowable period for 

expending PRF payments. 

Likely Respondents: PRF recipients 

who have received more than $10,000 in 

aggregate PRF payments during one of 

the Payment Received Periods outlined 

below and that agreed to the associated 

Terms and Conditions are required to 

submit a report in the PRF Reporting 

Portal during the applicable Reporting 

Time Period. 

Reporting period 

Payment received period 

(payments exceeding $10,000 in 

aggregate received) 

Reporting time period 

Period 1 ....................................... April 10, 2020, to June 30, 2020 ...................................................... July 1, 2021, to September 30, 2021. 

Period 2 ....................................... July 1, 2020, to December 31, 2020 ................................................ January 1, 2022, to March 31, 2022. 

Period 3 ....................................... January 1, 2021, to June 30, 2021 .................................................. July 1, 2022, to September 30, 2022. 

Period 4 ....................................... July 1, 2021, to December 31, 2021 ................................................ January 1, 2023, to March 31, 2023. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install, and utilize 

technology and systems for the purpose 

of collecting, validating and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total 

burden hours 

PRF Reporting Portal, Reporting Period 1 (Providers who 

received payments April 10, 2020, to June 30, 2020) ..... 126,831 1 126,831 5.6 710,254 

PRF Reporting Portal, Reporting Period 2 (Providers who 

received payments July 1, 2020, to December 31, 2020) 120,536 1 120,536 4.2 506,251 

PRF Reporting Portal, Reporting Period 3 (Providers who 

received payments January 1, 2021, to June 30, 2021) 19,962 1 19,962 5.6 111,787 

PRF Reporting Portal, Reporting Period 4 (Providers who 

received payments July 1, 2021, to December 31, 2021) 19,962 1 19,962 5.6 111,787 

Total .............................................................................. 287,291 ........................ 287,291 ........................ 1,440,079 

HRSA specifically requests comments 

on (1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions, (2) the accuracy of the 

estimated burden, (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2021–15885 Filed 7–23–21; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Tick-Borne Disease 

Working Group 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice. 

SUMMARY: As required by the Federal 

Advisory Committee Act, the 

Department of Health and Human 

Services (HHS) is hereby giving notice 

that the Tick-Borne Disease Working 

Group (TBDWG) will hold a virtual 

meeting. The meeting will be open to 

the public. For this meeting, TBDWG 

members will focus on plans to develop 

the next report due December 2022 on 

federal tick-borne activities and 

research, taking into consideration the 

2018 and 2020 reports. The 2022 report 

will address a wide range of topics 

related to tick-borne diseases, such as, 

surveillance, prevention, diagnosis, 

diagnostics, and treatment; identify 

advances made in research, as well as 

overlap and gaps in tick-borne disease 

research; and provide recommendations 

regarding any appropriate changes or 


jbell on DSKJLSW7X2PROD with NOTICES
40066 Federal Register / Vol. 86, No. 140 / Monday, July 26, 2021 / Notices 

improvements to such activities and 

research. 

DATES: The meeting will be held online 

via webcast on August 26, 2021 from 

approximately 9:00 a.m. to 5:00 p.m. ET 

(times are tentative and subject to 

change). The confirmed times and 

agenda items for the meeting will be 

posted on the TBDWG web page at 

https://www.hhs.gov/ash/advisorycommittees/tickbornedisease/meetings/ 

2021-08-26/index.html when this 

information becomes available. 

FOR FURTHER INFORMATION CONTACT: 

James Berger, Designated Federal Officer 

for the TBDWG; Office of Infectious 

Disease and HIV/AIDS Policy, Office of 

the Assistant Secretary for Health, 

Department of Health and Human 

Services, Mary E. Switzer Building, 330 

C Street SW, Suite L600, Washington, 

DC 20024. Email: tickbornedisease@

hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Registration information can be found 

on the meeting website at https://

www.hhs.gov/ash/advisory-committees/ 

tickbornedisease/meetings/2021-08-26/ 

index.html when it becomes available. 

The public will have an opportunity to 

present their views to the TBDWG orally 

during the meeting’s public comment 

session or by submitting a written 

public comment. Comments should be 

pertinent to the meeting discussion. 

Persons who wish to provide verbal or 

written public comment should review 

instructions at https://www.hhs.gov/ 

ash/advisory-committees/ 

tickbornedisease/meetings/2021-08-26/ 

index.html and respond by midnight 

August 17, 2021 ET. Verbal comments 

will be limited to three minutes each to 

accommodate as many speakers as 

possible during the 30 minute session. 

Written public comments will be 

accessible to the public on the TBDWG 

web page prior to the meeting. 

Background and Authority: The TickBorne Disease Working Group was 

established on August 10, 2017, in 

accordance with Section 2062 of the 

21st Century Cures Act, and the Federal 

Advisory Committee Act, 5 U.S.C. App., 

as amended, to provide expertise and 

review federal efforts related to all tickborne diseases, to help ensure 

interagency coordination and minimize 

overlap, and to examine research 

priorities. The TBDWG is required to 

submit a report to the HHS Secretary 

and Congress on their findings and any 

recommendations for the federal 

response to tick-borne disease every two 

years. 

Dated: July 9, 2021. 

James J. Berger, 

Designated Federal Officer, Tick-Borne 

Disease Working Group, Office of Infectious 

Disease and HIV/AIDS Policy. 

[FR Doc. 2021–15830 Filed 7–23–21; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Best Practices for Advancing Cultural 

Competency, Language Access and 

Sensitivity toward Asian Americans 

and Pacific Islanders 

Correction 

In notice document 2021–15168, 

appearing on pages 37757–37758 in the 

issue of Friday, July 16, 2021, make the 

following correction: 

On page 37757, in the third column, 

on the thirty-sixth line from the top, 

‘‘minorityhealth@hhs.gov’’ should read 

‘‘minorityhealth@hhs.gov.’’ 

[FR Doc. C1–2021–15168 Filed 7–23–21; 8:45 am] 

BILLING CODE 0099–10–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of The Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Advisory Committee on 

Research on Women’s Health. 

The meeting will be held as a virtual 

meeting and open to the public. 

Individuals who plan to view the virtual 

meeting and need special assistance or 

other reasonable accommodations to 

view the meeting, should notify the 

Contact Person listed below in advance 

of the meeting. The meeting will be 

videocast and can be accessed from the 

NIH Videocasting and Podcasting 

website (http://videocast.nih.gov/). 

Name of Committee: Advisory Committee 

on Research on Women’s Health. 

Date: September 1, 2021. 

Time: 1:30 p.m. to 2:30 p.m. 

Agenda: Presentation from the ACRWH 

Working Group on the Women’s Health 

Consensus Conference. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Samia Noursi, Ph.D., 

Associate Director, Science Policy, Planning, 

and Analysis, Office of Research on Women’s 

Health, National Institutes of Health, 6707 

Democracy Blvd., Room 402, Bethesda, MD 

20892, 301–496–9472, samia.noursi@nih.gov. 

Name of Committee: Advisory Committee 

on Research on Women’s Health. 

Date: October 20, 2021. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: Reports on Congressionally 

Recommended Women’s Health Priorities: 

Rising Maternal Morbidity and Mortality 

Rates; Rising Rates of Chronic Debilitating 

Conditions in Women; and Stagnant Cervical 

Cancer Survival Rates. 

Date: October 21, 2021. 

Time: 9:30 a.m. to 4:30 p.m. 

Agenda: Director’s Report, NCI Director 

Presentation, Women’s Health Consensus 

Conference Working Group Report, and 

concept clearances for various ORWH 

programs. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Samia Noursi, Ph.D., 

Associate Director, Science Policy, Planning, 

and Analysis, Office of Research on Women’s 

Health, National Institutes of Health, 6707 

Democracy Blvd., Room 402, Bethesda, MD 

20892, 301–496–9472, samia.noursi@nih.gov. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meetings. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

Information is also available on the 

Institute’s/Center’s home page: https://

orwh.od.nih.gov/, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: July 21, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–15865 Filed 7–23–21; 8:45 am] 

BILLING CODE 4140–01–P 


jbell on DSKJLSW7X2PROD with NOTICES